Renal cell carcinoma
Conditions
Interventions
from August 2019 to March 2020
Sponsors
Department of Urology, Kurume University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Clinically diagnosed as cT1 (including some cT1b) renal cancer by abdominal contrast-enhanced CT (or MRI examination for patients in whom contrast agents are not applicable), and partial nephrectomy is possible 2) No lymph node and metastasis to other intra-abdominal organs (cN0, cM0) by abdominal contrast-enhanced CT (MRI examination for patients who cannot adapt to contrast agents) 3) Chest CT and bone scintigraphy show no metastasis (cM0) 4) Single tumor 5) The latest test values within 6 weeks (42 days) before registration meet all of the criteria for the following items (WBC, Platelet, AST, ALT, T-Bil, Serum creatinine) 6) Aged 20 years or older at the time of informed consent 7) Written consent has been obtained from the patient to participate in the study
Exclusion criteria
Exclusion criteria: 1) Active double cancer 2) History of renal transplantation in the past 3) Receiving treatment for renal cancer within 6 months 4) Inability to discontinue anticoagulants 5) Anemia requiring blood transfusion or bleeding tendency 6) Patients with morbid obesity (BMI 35 over) 7) Patients undergoing dialysis 8) Pregnant women, women who may be pregnant, or women who are breastfeeding 9) Complications of psychiatric disease or psychiatric symptoms and judged to be difficult to participate in the study 10) Other reasons - the principal investigator or subinvestigator of the medical institution participating in this study determines that the participant is ineligible to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urine and blood biomarker for acute renal injury (L-FABP, NGAL, KIM-1) | — |
Countries
Japan
Contacts
Public ContactMitsunori Matsuo
Kurume University School of Medicine Department of Urology
Outcome results
None listed